# About Sermorelin Safe: An Independent Literature Digest

> Sermorelin Safe is an independent editorial project that summarizes the peer-reviewed research on sermorelin (GHRH(1-29)) — not a clinic, not a vendor, not medical advice.

## What this site is

Sermorelin Safe is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on sermorelin — the GHRH(1-29) growth-hormone-releasing peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word "safe" in the domain is not a promise about the compound. It is the editorial posture this site takes toward the literature: a due-diligence reading that asks whether a claim is actually backed by evidence before repeating it. "Safe" here means careful — checking the receipts, grading each finding, and refusing to launder a mouse study or a computer model into a human result.

## How we read the evidence

We grade every finding by the kind of study behind it. A randomized human trial, a 14-day pharmacokinetic study, an animal wound-healing model, and an in-silico drug-repurposing screen are four different grades of evidence, and we never write them as if they were the same. That discipline matters most for sermorelin's regenerative and oncology "frontier," where genuinely early signals are routinely inflated into clinical claims in marketing copy.

We also keep molecules straight: a great deal of the body-composition and cognition data circulating under sermorelin's name actually belongs to tesamorelin, a related but distinct GHRH analog. We attribute those findings where they belong. The point is not skepticism for its own sake — sermorelin has a real, replicated pediatric result and a well-characterized GH/IGF-1 effect. The point is to keep the proven and the unproven clearly separated.

## What we are not

The "safe" modifier in this site's name is editorial framing — a position this publisher occupies relative to the literature, not a claim about any service. This site does not offer treatment, consultation, prescriptions, or product. It does not tell anyone what to take. It summarizes what published studies measured, cites the sources, and grades the strength of the evidence so a reader can do their own homework from primary literature.

---

An engineering-datasheet reading of the sermorelin record — every GHRH(1-29) figure logged to its study and stamped with an evidence grade, the proven pediatric trial kept apart from the borrowed tesamorelin numbers and both apart from the in-silico oncology and preclinical regenerative signals; no clinic behind the spec sheet and nothing here dosed, compounded, prescribed, or sold.